OBJECTIVE: The aim of the present prospective and naturalistic study was to examine the effects of antipsychotic medication on weight and serum levels of lipids, glucose and insulin in first-episode psychosis patients. METHOD: Fifty-six patients admitted to the Singapore Early Psychosis Intervention Programme participated in this study. They were assessed at baseline (i.e. within 72 h of starting antipsychotics), and 6 months later. Weight (kg) and height (m) were measured and body mass index (BMI) was calculated. Blood samples were taken after a 12 h overnight fast. Choice of antipsychotics was based on the treating physician's clinical decision. Total cumulative Chlorpromazine (CPZ) equivalent of antipsychotic exposure during the 6 months was calculated. Statistical analyses were carried out for comparisons between baseline and 6 months, and for the two outcome event groups of > or =7% versus <7% weight gain. Where appropriate, confounders were controlled. RESULTS AND CONCLUSION: There were significant increases in BMI, serum levels of triglyceride, low-density lipoprotein and total cholesterol from baseline to 6 months. Mean increase in weight was 6.2+/-7.0 kg (p < 0.05) and 65% of the patients had clinically significant weight gain (i.e. > or =7% increase from baseline). On logistic regression lower baseline BMI, female gender, and younger age, were associated with clinically significant weight gain.
OBJECTIVE: The aim of the present prospective and naturalistic study was to examine the effects of antipsychotic medication on weight and serum levels of lipids, glucose and insulin in first-episode psychosispatients. METHOD: Fifty-six patients admitted to the Singapore Early Psychosis Intervention Programme participated in this study. They were assessed at baseline (i.e. within 72 h of starting antipsychotics), and 6 months later. Weight (kg) and height (m) were measured and body mass index (BMI) was calculated. Blood samples were taken after a 12 h overnight fast. Choice of antipsychotics was based on the treating physician's clinical decision. Total cumulative Chlorpromazine (CPZ) equivalent of antipsychotic exposure during the 6 months was calculated. Statistical analyses were carried out for comparisons between baseline and 6 months, and for the two outcome event groups of > or =7% versus <7% weight gain. Where appropriate, confounders were controlled. RESULTS AND CONCLUSION: There were significant increases in BMI, serum levels of triglyceride, low-density lipoprotein and total cholesterol from baseline to 6 months. Mean increase in weight was 6.2+/-7.0 kg (p < 0.05) and 65% of the patients had clinically significant weight gain (i.e. > or =7% increase from baseline). On logistic regression lower baseline BMI, female gender, and younger age, were associated with clinically significant weight gain.
Authors: Kieran J Davey; Siobhain M O'Mahony; Harriet Schellekens; Orla O'Sullivan; John Bienenstock; Paul D Cotter; Timothy G Dinan; John F Cryan Journal: Psychopharmacology (Berl) Date: 2012-01-11 Impact factor: 4.530
Authors: Benjamin J Keeney; Deborah Fulton-Kehoe; Thomas M Wickizer; Judith A Turner; Kwun Chuen Gary Chan; Gary M Franklin Journal: J Occup Environ Med Date: 2013-03 Impact factor: 2.162
Authors: Christoph U Correll; Peter Manu; Vladimir Olshanskiy; Barbara Napolitano; John M Kane; Anil K Malhotra Journal: JAMA Date: 2009-10-28 Impact factor: 56.272
Authors: Kristina M Deligiannidis; Anthony J Rothschild; Bruce A Barton; Aimee R Kroll-Desrosiers; Barnett S Meyers; Alastair J Flint; Ellen M Whyte; Benoit H Mulsant Journal: J Clin Psychiatry Date: 2013-10 Impact factor: 4.384
Authors: Kurtis J Swanson; Emily Joachim; Annamalai Arunachalam; Fahad Aziz; Neetika Garg; Maha Mohamed; Arjang Djamali; Robert R Redfield; Dixon B Kaufman; Jon Odorico; Didier Mandelbrot; Sandesh Parajuli Journal: Transplant Direct Date: 2020-02-24